Revolution Medicines Inc. (RVMD)
NASDAQ: RVMD · Biological Products, (No Diagnostic Substances) · Redwood City, CA
Our rating: Positive
Call changed from Neutral to Positive at $177.65, moderate conviction, November 5, 2026.
Breaks if: The Positive call turns wrong if any lead program misses a primary endpoint in a pivotal or registration-enabling trial reported within the next 12 months — one major readout failure at this valuation would warrant a reassessment toward Cautious, as the entire equity value rests on pipeline probability rather than on earnings power that already exists. On price, if the stock falls more than 40% from today's $177.65 within 180 trading days, the market would be signaling a material repricing of clinical risk that the current thesis cannot absorb.
Key figures
| Market value | $34.9B |
|---|---|
| Revenue, last 12 months | n/a |
| Net income, last 12 months | −$1.9B |
| Free cash flow, last 12 months | −$1.4B |
| Price to earnings | n/a |
| Free cash flow yield | −4.1% |
| Dividend yield | 0.0% |
| Operating margin | n/a |
| Return on equity | −93.6% |
| Beta to the S&P 500 | 1.09 |
| Volatility, annualized | 55.6% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $198M | n/a | $-1.90 | −$419M |
| June 30, 2026 | n/a | n/a | $-3.06 | −$390M |
| March 31, 2026 | n/a | n/a | $-2.29 | −$356M |
| December 31, 2025 | $0.00 | n/a | $-1.89 | −$276M |
| September 30, 2025 | $0.00 | n/a | $-1.61 | −$211M |
| June 30, 2025 | n/a | n/a | $-1.31 | −$229M |
| March 31, 2025 | n/a | n/a | $-1.13 | −$198M |
| December 31, 2024 | $0.00 | −100.0% | $-1.13 | −$140M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Diluted earnings per share are above zero: Claude 2%, Gemini 5%, Mistral 3%
- Free cash flow for the quarter is above zero: Claude 2%, Gemini 2%, Mistral 2%
17 ledger entries and 19 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.